The global bronchodilators market is comprised of drugs that relieve bronchospasm and relaxation of bronchial smooth muscle to relieve signs and symptoms of narrowing airways, including drugs such as beta 2 agonists, anticholinergics, and theophyllines. Key bronchodilators available include albuterol, levalbuterol, ipratropium, tiotropium, theophylline, salmeterol, and formoterol amongst others. Bronchodilators find wide application in treatment of respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD).
Key Takeaways
Key players operating in the global bronchodilators market are GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva. GSK plc. dominates the bronchodilators market garnering over 15% share with key brands like Advair and Ventolin. Key opportunities in the market include development of fixed-dose combination therapies, long acting bronchodilators promising better patient compliance and combination inhalers integrating corticosteroids. The market is witnessing increased global expansion driven by rising incidences of respiratory illnesses, growth in healthcare infrastructure and spending in emerging markets of Asia Pacific and Latin America.
Market drivers
The key driver for the Bronchodilators Market is the rising prevalence of respiratory diseases globally. As per the WHO, around 235 million people suffer from asthma and about 65 million have COPD worldwide. Increasing pollution levels, growing smoking rates and aging population are major factors for rising respiratory illnesses. The market is further fueled by availability of generic versions and over-the-counter drugs along with favorable reimbursement policies in developed regions.
PEST Analysis
Political: Regulations around product development, approval and marketing of bronchodilators can impact the market. Changes in the pricing, coverage, and reimbursement policies also affect sales and profitability.
Economic: Economic growth, healthcare expenditure levels, pricing pressures and fluctuations in currency exchange rates influence industry sales and profitability. Research and development investments depend on the overall economic conditions.
Social: Growing incidence of respiratory diseases, increasing elderly population and changing lifestyle habits are key drivers. However, growth can be limited by social stigmas around dependence on medication and side effects.
Technological: Advances in drug delivery systems, device connectivity and digital health solutions provide opportunities. Innovation in therapeutic areas and development of combination therapies help address unmet needs and drive market expansion.
The global bronchodilators market in terms of value is concentrated majorly in North America and Europe. US and major European countries have an established healthcare system with good insurance coverage and reimbursement policies for respiratory medications. The growing elderly population and higher per capita healthcare expenditure in these regions contribute to the market concentration.
The Asia Pacific region is the fastest growing market for bronchodilators globally. Factors such as rising incidence of respiratory ailments, growing patient awareness, improving access to healthcare facilities and increasing healthcare spending are fueling strong demand. Countries like China and India with their large population bases present lucrative opportunities for market participants. Manufacturers are focusing on these emerging countries by setting up local manufacturing plants and expansion of distribution networks.
Get more insights on Bronchodilators Market
